Olubukola Ayodele: Attending the IKCS Europe 2024 conference in the picturesque seaside town of Sitges
Olubukola Ayodele, Consultant Medical Oncologist at Leicester Cancer Research Centre, shared on LinkedIn:
“I’m currently attending the IKCS Europe 2024 conference in the picturesque seaside town of Sitges. It’s been wonderful to connect with so many colleagues who are dedicated to treating kidney cancer.
The management of RCC has undergone a significant shift in treatment approaches, with impressive progress made in systemic therapy for advanced RCC.
In addition to relying on data from randomized clinical trials, it’s crucial to stay informed about the practices of our colleagues when it comes to sequencing treatments and managing toxicities.
As a strong proponent of common-sense oncology, I was thrilled to hear Bernard Escudier’s presentation on the need to move beyond suboptimal comparators. It’s morally unacceptable that so many randomized trials have been conducted with such inadequate controls. We must take a stand and refuse to participate in clinical trials that are not up to standard. Sunitinib and everolimus should not be used as comparators for first and second-line mRCC trials, respectively. Additionally, the primary endpoint for first-line therapy should be overall survival, not progression-free survival.
It’s crucial that we hold studies to a high standard, and that means ensuring that comparators and endpoints are appropriate. Anything less is simply not acceptable.”
Source: Olubukola Ayodele/LinkedIn
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023